|
Welcome Cancer Patients and Family Members
Poly-MVA Introduction
Poly-MVA is a powerful antioxidant dietary supplement that
is being recommended by Practitioners in the
United States and internationally (see Physician
List) as superior nutritional support for
thousands of patients.
Poly-MVA is distributed as a GMP compliant dietary supplement based on 40 years of scientific research performed
by biochemist and cancer researcher, Dr. Merrill Garnett, who painstakingly developed the Lipoic Acid Palladium
complex (LAPd). What makes Poly-MVA unique is the special, proprietary manufacturing process by which Lipoic Acid is bonded to the mineral Palladium. No other company produces any product similar to, or as effective
as, Poly-MVA because of the patented preparation and bonding process through which LAPd is manufactured.
Mary Higgins
UTERINE CANCER
"I shared the information
about Poly-MVA with Dr. Ramin Mirhashemi, my Gynoncologist at Torrance Memorial Hospital. He was so amazed at my
rapid recovery and how I was able to maintain my weight. The chemo nurse was very impressed with my lab results
and said I did not look like a cancer patient. They could not believe how quickly I was recovering. When you look
at my laboratory reports you can see the rapid improvement. I did receive a miracle and I know that God has given
you the formula for helping people with life threatening diseases to bring the body back into balance. " |
POLY-MVA ALLEVIATES
MITOCHONDRIAL OXIDATIVE STRESS
Jefferson researchers provide
genetic evidence
that antioxidants can help treat cancer
Posted On: February 15, 2011 - 3:30pm
PHILADELPHIA—Researchers from Jefferson's Kimmel Cancer Center have genetic evidence suggesting the antioxidant drugs currently used to treat lung disease, malaria and even the common cold can also help prevent and treat cancers because they fight
against mitochondrial oxidative stress—a culprit in driving tumor growth.
For the first time, the researchers show that loss of the tumor suppressor protein Caveolin-1 (Cav-1) induces mitochondrial
oxidative stress in the stromal micro-environment, a process that fuels cancer cells in most common types of breast cancer.
"Now we have genetic proof that mitochondrial oxidative stress is important for driving tumor growth,"
said lead researcher Michael P. Lisanti,
M.D., Ph.D., professor of cancer biology at Jefferson Medical College of Thomas Jefferson University and member
of the Kimmel Cancer Center at Jefferson. "This means we need to make anti-cancer drugs that specially target this type of oxidative
stress. And there are already antioxidant drugs out there on the market as dietary
supplements, like N-acetyl cysteine."
These findings were published in the online February
15 issue of Cancer Biology & Therapy.
Lisanti's lab previously discovered Cav-1 as a biomarker that functions as a tumor suppressor and is the single
strongest predictor of breast cancer patient outcome. For example, if a woman has triple negative breast cancer
and is Cav-1 positive in the stroma, her survival is greater than 75 percent at 12 years, versus less than 10 percent
at 5 years if she doesn't have the Cav-1 protein, according to Dr. Lisanti.
The researchers also established Cav-1's role
in oxidative stress and tumor growth; however,
where that stress originates and its mechanism(s) were unclear.
The researchers report that the loss of Cav-1
increases mitochondrial
oxidative stress in the
tumor stroma, increasing both tumor mass and tumor volume by four-fold, without any increase in tumor angiogenesis.
"Antioxidants have been associated with cancer reducing effects—beta carotene, for example—but the mechanisms,
the genetic evidence, has been lacking," Dr. Lisanti said. "This study provides the necessary genetic evidence that reducing oxidative stress in the body will decrease tumor growth."
Currently, anti-cancer drugs
targeting oxidative stress are not used because is it commonly thought they will reduce the effectiveness of certain
chemotherapies, which increase
oxidative stress.
"We are not taking advantage
of the available drugs that reduce oxidative stress and autophagy, including metformin, chloroquine and N-acetyl
cysteine," Dr. Lisanti said. "Now that we have genetic proof that oxidative stress and resulting autophagy are important
for driving tumor growth,
we should re-consider using
antioxidants and autophagy
inhibitors as anti-cancer agents."
Read entire article here
ANTIOXIDANTS BENEFIT CANCER
PATIENTS
If you have started or are about to start Chemo & Radiation Treatments, click below.
5 PEER REVIEWED
ANTIOXIDANT CLINICAL STUDIES
Click Here
"Antioxidants provide greater cancer destruction & fewer side effects"
QUOTES FROM AUTHORS
|
CHARLES SIMONE, M.D.
|
|
"If your doctor tells you not to take antioxidant
supplements or nutrients during your treatment, ask him or her to show you the rationale for this decision from
a peer-reviewed journal," Simone says. "It cannot be produced because there isn't any."
The bottom line, he says, is that "our
study shows that millions of
cancer patients who receive chemotherapy and/or radiation therapy should take antioxidants and other nutrients because there is no interference, there is greater cancer destruction, there are fewer
side effects, and about two-thirds of the patients live longer." |
| |
|
|
| |
|
|
|
DR. ROBERT NEWMAN
|
|
Co-author Dr. Robert Newman, Professor of
Cancer Medicine at M. D. Anderson Cancer Center said, “This study, along with the evolving understanding of antioxidant-chemotherapy interactions,
suggests that the previously held beliefs about interference do not pertain to clinical treatment.” |
| |
|
|
| |
|
|
|
KEITH BLOCK, MD
|
|
“This review demonstrates that there is no scientific
support for the blanket objection to using antioxidants during chemotherapy. In addition, it also appears that these supplements may help mitigate the side effects of chemotherapy,” said Keith I. Block, MD, lead author of the study and Medical Director of the Block Center for Integrative Cancer Treatment.
“This is significant because it
increases the likelihood that patients will be able to complete their treatment.” |
| |
|
|
Daniel Palomino
COLON CANCER
"Before my surgery, I went
through chemotherapy and radiation which were very hard on my system.... I had bone and muscle pain, loss of appetite
and an incredible amount of fatigue. Now that I've been on Poly MVA for a few months, I can really tell that it's
made a difference. I used to spend 1/3 of the day recovering due to fatigue. Now, I walk 2-3 miles a day and go
to the gym 3 times a week." |
(also see Quality of Life Studies section)
POLY-MVA: 40 years of Scientific Research
Dr. Merrill Garnett is a research chemist and the head of
the Garnett McKeen Laboratory in Stony Brook, New York. Dr. Garnett is the inventor and recipient of multiple U.S.
patents for palladium lipoic complexes. For nearly 40 years, Dr. Garnett has probed the secrets of molecular biology
and the mysteries of cells. He saw cellular dysfunction as the failure of cells to regenerate normally in a default
mode; instead, cloning itself in a deranged state over and over again. He theorized that this failure to mature was a problem of energetics in the cells metabolic processes
via the cells energy transport chain which occurs through electron transfer.
While definitive studies on Poly-MVA's effect
in human nutrition and health are ongoing, existing published reports as well as two Quality of Life Studies (2.5
& 4 year studies, respectively) including information from Physicians as well as patients indicate that the
active ingredients in Poly-MVA may be beneficial in optimizing cellular function. This cellular support results
in proper regulation and increased production of cellular energy. For Cancer Patients, this action is clearly highly
supportive.
Dr. Merrill Garnett
Research Chemist
Poly-MVA(LAPd complex) Inventor
|
Curriculum Vitae,
Patents & Monographs
.
Titles of 57 Published
Research Articles
.
Click here
|
Poly-MVA
Published Research
.
Review Abstracts and
Published Articles
.
Click here
|
Radiation
Oncology Research
.
Protective effects of Poly-MVA during Radiation Exposure
.
Click here
|
Linda Richert
BREAST CANCER
"I was diagnosed with Stage
IIIB breast cancer in May of 2007. I started on Poly-MVA right away. After six weeks on Poly and after only two
chemo sessions, a sonogram showed that the lymph nodes under my arm were returning to normal. That amazed the doctor.
I also never got sick from the chemo. I did get nauseated but did not throw up. I am now cancer free and it is
a miracle after such a poor original diagnosis. " |
Mechanism of action
For clarification, there is no free lipoic
acid or palladium in the Poly-MVA formulation. These two components are irreversibly bound, resulting in a new
compound. Dr. Garnett engineered Poly-MVA in this manner to create a polymer that is soluble in both fat and water
(meaning that it will travel to all locations of the body as well as cross the blood brain barrier). Bound in this
fashion, the palladium and lipoic
acid create a universally unique compound with extraordinary properties. Poly-MVA (LAPd) is a liquid crystal that works by collecting energy from free radicals
and transferring that energy from membrane fatty acids to DNA via the mitochondria. Therefore, by its structural
nature and action as a redox shuttle, Poly-MVA
(LAPd) can both quench radicals as well as provide energy to the mitochondria. In layman terms, Poly-MVA appears to provide an ongoing source of cellular protection
to healthy aerobic cells under extreme duress.
(see Published article Poly-MVA
gives protection against radiation illness
)
Poly-MVA supports the Electron
Transport Chain
In healthy aerobic cells, Poly-MVA transfers
electrical charge (energy) from the fatty acids (that make up the cells membrane) via the ELECTRON
TRANSPORT CHAIN in the mitochondria
(the cellular organelle responsible
for energy production) supporting
optimal cellular function. However, anaerobic
cells, that function in a hypoxic
(low oxygen) environment, lack
the oxygen pathways necessary to distribute the electrical charge.
Hypothetical Graphic showing Poly-MVA providing
Electrical energy to THE CELL via the MITOCHONDRIA(the
cells battery).
Published scientific reports indicate that
Poly-MVA acts as an efficient aerobic catalyst which leads to improved oxygen utilization and energy at the cellular
level in healthy cells, which
utilize aerobic metabolism, without
providing the same benefits to anaerobic cells which are devoid of a proper electron transport chain infrastructure(see graphic below). This is the cellular mechanism of action that has been documented and is resulting
in the dramatic benefits reported by Physicians and Patients.
According to Dr. Frank Antonawich, research scientist and instructor for St. Josephs College who researches lipoic
acid-palladium complexes, this selective cellular metabolic support provided by Poly-MVA(LAPd) is helpful and supportive to normal aerobic (high-oxygen) cells
whereas anaerobic (low-oxygen) cells produce energy differently and have adapted to a hypoxic (low-oxygen) environment which can not properly utilize this electron transfer.
Therefore, anaerobic cells, that function in a hypoxic (low oxygen) environment, lack the oxygen pathways necessary to distribute the electrical charge.
|
